

# A feedback loop between nonsense-mediated decay and the retrogene *DUX4* in facioscapulohumeral muscular dystrophy

Qing Feng<sup>1,2</sup>, Lauren Snider<sup>3</sup>, Sujatha Jagannathan<sup>1,2,3</sup>, Rabi Tawil<sup>4</sup>,  
Silvère M van der Maarel<sup>5</sup>, Stephen J Tapscott<sup>3,6\*</sup>, Robert K Bradley<sup>1,2\*</sup>

<sup>1</sup>Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States; <sup>2</sup>Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States; <sup>3</sup>Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, United States; <sup>4</sup>Department of Neurology, University of Rochester, Rochester, United States; <sup>5</sup>Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands; <sup>6</sup>Department of Neurology, University of Washington, Seattle, United States

**Abstract** Facioscapulohumeral muscular dystrophy (FSHD) is a muscular dystrophy caused by inefficient epigenetic repression of the D4Z4 macrosatellite array and somatic expression of the *DUX4* retrogene. *DUX4* is a double homeobox transcription factor that is normally expressed in the testis and causes apoptosis and FSHD when misexpressed in skeletal muscle. The mechanism(s) of *DUX4* toxicity in muscle is incompletely understood. We report that *DUX4*-triggered proteolytic degradation of UPF1, a central component of the nonsense-mediated decay (NMD) machinery, is associated with profound NMD inhibition, resulting in global accumulation of RNAs normally degraded as NMD substrates. *DUX4* mRNA is itself degraded by NMD, such that inhibition of NMD by *DUX4* protein stabilizes *DUX4* mRNA through a double-negative feedback loop in FSHD muscle cells. This feedback loop illustrates an unexpected mode of autoregulatory behavior of a transcription factor, is consistent with 'bursts' of *DUX4* expression in FSHD muscle, and has implications for FSHD pathogenesis.

DOI: [10.7554/eLife.04996.001](https://doi.org/10.7554/eLife.04996.001)

\*For correspondence: [stapscot@fhcrc.org](mailto:stapscot@fhcrc.org) (SJT); [rbradley@fhcrc.org](mailto:rbradley@fhcrc.org) (RKB)

**Competing interests:** The authors declare that no competing interests exist.


**Funding:** See page 11

**Received:** 01 October 2014

**Accepted:** 07 January 2015

**Published:** 07 January 2015

**Reviewing editor:** Rachel Green, HHMI, Johns Hopkins University School of Medicine, United States

 Copyright Feng et al. This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

## Main text

Facioscapulohumeral muscular dystrophy (FSHD) is typically an adult-onset muscular dystrophy characterized by muscle weakness initially affecting the face (facio), shoulders (scapulo), and upper arms (humeral). FSHD is caused by decreased epigenetic repression of the D4Z4 macrosatellite array in the subtelomeric region of chromosome 4q, due to either D4Z4 repeat contractions ([Lemmers et al., 2010](#)) or mutations affecting *trans*-acting epigenetic regulators of the D4Z4 repeat such as SMCHD1 ([Lemmers et al., 2012](#)), which results in the misexpression of *DUX4* mRNA in skeletal muscle and possibly other somatic tissues. *DUX4* encodes a double homeobox transcription factor that activates germline genes and repetitive elements ([Geng et al., 2012](#)) and causes apoptosis and atrophic myotube formation when misexpressed in skeletal muscle ([Kowaljow et al., 2007](#); [Vanderplanck et al., 2011](#); [Wallace et al., 2011](#); [Mitsuhashi et al., 2012](#)). *DUX4* is expressed in only a small fraction of nuclei ([Snider et al., 2010](#)), likely due to occasional 'bursts' of *DUX4* expression. However, the mechanism(s) regulating *DUX4* expression and toxicity remain incompletely understood.

We previously ectopically expressed *DUX4* in immortalized (54-1) and primary (MB135) myoblasts and used RNA-seq to identify coding genes, repetitive elements, and non-coding RNAs induced by *DUX4* ([Young et al., 2013](#)). Further analysis of this data showed that *DUX4* expression also resulted in

**eLife digest** Genes are sequences of DNA that contain instructions for the cell that must be carefully controlled because it is not always appropriate or safe for these instructions to be followed. When genes are active, copies of the DNA are made using molecules of ribonucleic acid (RNA) and these can then be used as templates to make proteins.

One way genes can be controlled is by adding small chemical tags that mark them out to be activated or deactivated, known as epigenetic control. The muscle disease facioscapulohumeral muscular dystrophy (FSHD) is caused by the loss of the chemical tags that normally keep certain genes switched off in many cell types. One of these genes is *DUX4*, which in healthy males is normally only active in the testes, but in FSHD patients it is also active in other parts of the body.

Another way to control genes is by nonsense-mediated decay, where incorrect or incomplete RNA molecules are destroyed before they can be used to make defective proteins. In this study, Feng et al. show that when *DUX4* is activated following the failure of epigenetic control in FSHD patients, the effectiveness of nonsense-mediated decay is also reduced. This results in the build-up of incorrect RNA molecules inside muscle cells, which can harm the cell. In fact, 13% of the incorrect RNA molecules that are normally destroyed in cells were found at higher levels when *DUX4* was active.

To investigate how *DUX4* could work, Feng et al. focused on another gene called *UPF1* because cells without the protein encoded by this gene have similar defects in nonsense-mediated decay as cells with active *DUX4*. No difference was found in how often the *UPF1* gene is activated in FSHD cells and normal cells. However, the amount of the protein encoded by *UPF1* was lower in cells with FSHD than in normal muscle cells. The experiments show that the protein encoded by *UPF1* is broken down as a result of the activation of the *DUX4* gene, leading to problems with nonsense-mediated decay, which may result in the worsening of FSHD symptoms.


The twist in the tale is that *DUX4* itself is also controlled by nonsense-mediated decay under normal circumstances. Therefore, in diseased cells, a failure in epigenetic control allows *DUX4* to prevent its own destruction by tampering with nonsense-mediated decay. These findings offer new insights into the role of the *DUX4* gene in FSHD. The next step is to test whether these defects in nonsense-mediated decay can explain any of the symptoms of FSHD, such as muscle inflammation.

DOI: [10.7554/eLife.04996.002](https://doi.org/10.7554/eLife.04996.002)

the increased abundance of many coding RNA isoforms containing premature translation termination codons upstream of splice junctions. These isoforms, which are predicted substrates for degradation by nonsense-mediated decay (NMD), were present at very low levels in control myoblasts. Following *DUX4* expression, however, many such predicted NMD substrates increased in abundance and in many cases became the predominant mRNA product of the parent gene. For example, an isoform of the *SRSF3* gene containing a well-characterized NMD-inducing cassette exon (Lareau et al., 2007; Ni et al., 2007) was present at low levels prior to *DUX4* expression but became the dominant isoform thereafter in both 54-1 and MB135 cells (Figure 1A–B).

To determine whether increased levels of such normally degraded mRNAs were associated with reduced NMD efficiency, we used an exogenous reporter system. We transfected plasmids encoding either the wild-type  $\beta$ -globin open reading frame or  $\beta$ -globin with a premature termination codon that induces degradation by NMD (Zhang et al., 1998). Relative levels of the  $\beta$ -globin NMD substrate were twofold higher in *DUX4*-expressing vs control myoblasts, indicating that NMD is indeed compromised by *DUX4* (Figure 1C).

We then determined how reduced NMD efficiency affected global levels of predicted NMD substrates. Restricting to cassette exon splicing events where one isoform, but not both, was a predicted NMD substrate, we found that ~13% of such predicted NMD substrates increased following *DUX4* expression, while ~1.6% decreased, in 54-1 cells (Figure 1D). Impaired NMD also caused accumulation of aberrant mRNAs resulting from mis-splicing or incomplete splicing, which are common byproducts of the stochastic nature of the splicing process (Weischenfeldt et al., 2012). We identified and quantified alternative splicing of annotated constitutive junctions, finding that ~13% of such junctions exhibited increased aberrant splicing in *DUX4*-expressing vs control cells, while only ~0.25% exhibited decreased aberrant splicing (Figure 1E). The vast majority of these novel products of annotated constitutive junctions were present at very low or undetectable levels in control 54-1 myoblasts.



**Figure 1.** *DUX4* expression inhibits nonsense-mediated decay. **(A)** RNA-seq read coverage of the *SRSF3* gene in control and *DUX4*-expressing myoblasts. 54-1, immortalized myoblasts; MB135, primary myoblasts. Purple shading, NMD-inducing cassette exon. Red stop sign, termination codon. **(B)** Inclusion of the premature termination codon-containing cassette exon of *SRSF3* illustrated in **(A)**. Error bars, 95% confidence intervals as estimated by MISO (Katz et al., 2010). **(C)** Relative levels of transcripts produced from NMD reporter plasmids encoding either premature termination codon-containing (top) or normal (bottom)  $\beta$ -globin (GI). Bar plot illustrates the ratio NMD(+)/NMD(-) of transcripts from the NMD(+) and NMD(-) constructs. **(D)** Isoform ratios of predicted NMD substrates generated by cassette exon alternative splicing in control and *DUX4*-expressing myoblasts (54-1 cells). Red/blue, cassette exons exhibiting increases/decreases of  $\geq 10\%$  in isoform ratios for the isoforms that are predicted NMD substrates. **(E)** Isoform ratios of mis-spliced isoforms of annotated constitutive splice junctions generated by abnormal 5' and 3' splice site recognition (54-1 cells). Color as in **(D)**. **(F)** Global increases and decreases in relative levels of predicted NMD substrates generated by differential splicing. Annotated alternative splicing events are illustrated in upper panel, and alternative splicing and intron retention of annotated constitutively spliced junctions are illustrated in lower panel. Up/down arrows, percentages of predicted NMD substrates generated by alternative splicing exhibiting increases/decreases of  $\geq 10\%$  in isoform ratios in *DUX4*-expressing vs control cells. Enrichment for increased vs decreased levels of NMD substrates indicated in columns three and six.

DOI: 10.7554/eLife.04996.003

The following figure supplement is available for figure 1:

**Figure supplement 1.** *DUX4*-induced NMD inhibition is not a side effect of *DUX4* toxicity.

DOI: 10.7554/eLife.04996.004

We next extended this analysis to all classes of splicing events, including mis-splicing and intron retention of constitutive splice junctions. *DUX4* expression caused increased levels of predicted NMD substrates for all classes of splicing events in both 54-1 and MB135 cells (**Figure 1F**). These increases were generally more extreme in 54-1 than in MB135 cells, likely due to the ~15-fold higher *DUX4* expression achieved in 54-1 vs MB135 cells as well as the longer time period allowed for infection (48 hr vs 24 hr).

High levels of NMD substrates in *DUX4*-expressing cells were not simply a side effect of *DUX4*-induced apoptosis. *TP53* knock-down (KD) prevented apoptosis following *DUX4* expression in normal myoblasts, confirming previous reports that *DUX4* toxicity is p53-dependent (**Wallace et al., 2011**). However, *TP53* KD did not prevent *DUX4*-induced NMD inhibition (**Figure 1—figure supplement 1**).


*DUX4* could potentially inhibit NMD by transcriptionally repressing components of the NMD machinery. However, no UPF or SMG NMD factors exhibited decreased mRNA levels following *DUX4* expression, and most were up-regulated by two- to fourfold (**Figure 2A**). This expression pattern was reminiscent of a recent report that mRNA levels of most NMD factors increase following the knock-down of *UPF1*, encoding a central component of the NMD machinery (**Huang et al., 2011**). Therefore, we hypothesized that *UPF1* mRNA and protein levels might be decoupled in *DUX4*-expressing cells. We measured levels of *UPF1*, which was not transcriptionally up-regulated in *DUX4*-expressing cells, and *UPF3B* and *SMG7*, which were transcriptionally up-regulated in response to *DUX4*. *UPF1* protein levels were markedly lower in *DUX4*-expressing myoblasts than in control myoblasts, as were *SMG7* levels, although to a lesser extent. In contrast, *UPF3B* levels were unaffected by *DUX4* expression (**Figure 2B**).

To determine whether decreased *UPF1* temporally correlates with *DUX4*-induced inefficient NMD, we conducted a time course following *DUX4* expression in myoblasts. *DUX4* was robustly detectable 12–14 hr after lentiviral infection, coincident with the beginning of a sharp decrease in *UPF1* levels (**Figure 2C–D**). *SMG7* showed a more modest decrease through the time course, while *UPF3B* levels were relatively constant. NMD substrates produced from the  $\beta$ -globin reporter, as well as endogenously produced from the *SRSF2* and *SRSF3* genes, exhibited increased levels 12–14 hr after lentiviral expression (**Figure 2E–F**). The close temporal coupling between *DUX4* protein production, decreased *UPF1* levels, and increased levels of both endogenous and exogenous NMD substrates suggests that insufficient levels of *UPF1*—and perhaps additional NMD machinery components such as *SMG7*—may contribute to inefficient NMD in *DUX4*-expressing cells.

The rapid decrease in *UPF1* levels that we observed suggested that *DUX4* might trigger *UPF1* degradation. To test this, we treated *DUX4*-expressing or control myoblasts with MG132 to inhibit the proteasome. MG132 treatment restored normal *UPF1* levels in *DUX4*-expressing myoblasts, while *UPF1* levels in control myoblasts were unaffected (**Figure 2G–H**). As proteasome inhibition inhibits normal translation (**Cowan and Morley, 2004; Mazroui et al., 2007**) and therefore NMD, we were unable to test whether the restoration of normal *UPF1* levels by proteasomal inhibition rescued NMD. However, the close temporal relationship between the onset of decreased *UPF1* levels and increased NMD substrates strongly suggests that *UPF1* degradation contributes to NMD inhibition in *DUX4*-expressing cells.

Both *DUX4* isoforms encoding the full-length protein contain a constitutively spliced intron within their 3' UTRs, rendering them likely NMD substrates (**Figure 3A**). To test this, we used cells isolated from FSHD1 (54-2, which are isogenic to normal 54-1 cells but carry a contracted D4Z4 array) and FSHD2 (MB200) skeletal muscle (**Krom et al., 2012; Schoenberg and Maquat, 2012; Young et al., 2013**). We knocked down *UPF1* in 54-2 and MB200 myoblasts to 24.3% and 32.4% of normal protein levels, respectively, and differentiated these myoblasts to myotubes to stimulate *DUX4* transcription. *DUX4* mRNA was expressed at approximately fourfold higher levels in *UPF1* KD vs control KD myotubes, as was *ZSCAN4* mRNA, which is transcriptionally activated by *DUX4* (**Figure 3B–D**).

We next sought to determine whether the intron-containing 3' UTR of *DUX4* contributed to the degradation of *DUX4* mRNA by NMD. We created chimeric constructs containing the  $\beta$ -globin open reading frame followed by either the complete *DUX4* 3' UTR or the *DUX4* 3' UTR with the second intron removed (**Figure 3E**). We focused on the constitutively spliced second intron within the 3' UTR because it lies 100 nt downstream of the termination codon, and therefore it is predicted to trigger NMD. Transcripts from the chimeric construct containing the complete *DUX4* 3' UTR increased twofold following *UPF1* KD in normal myoblasts—a substantial but smaller increase than we observed for the endogenous *DUX4* mRNA, perhaps due to the chimeric nature of the  $\beta$ -globin + *DUX4* 3' UTR construct—while



**Figure 2.** DUX4 destabilizes UPF1 via the proteasome. **(A)** Relative mRNA levels of NMD factors in *DUX4*-expressing vs control myoblasts (54-1 cells). Red, up-regulation by  $\geq 1.5$ -fold. **(B)** Immunoblot for NMD factors UPF1, SMG7, and UPF3B in *DUX4*-expressing and control myoblasts (54-1 cells) at 36 hr post-infection. H3, histone H3 (loading control). *Figure 2. Continued on next page*



Figure 2. Continued

(C) Immunoblot of total protein from a 36-hr time course of *DUX4*-expressing and control myoblasts (54-1 cells). H3, histone H3. Loading Control, a nonspecific band that serves as an additional loading control. (D) Quantification of UPF1 protein level from the immunoblot presented in (C), normalized to the nonspecific band that serves as a loading control. (E) Relative levels of transcripts produced from the NMD(+) and NMD(-)  $\beta$ -globin reporter plasmids. (F) Isoform ratios of endogenously produced NMD-degraded isoforms of *SRSF2* and *SRSF3*. Time course identical to (C). Error bars, standard deviation. (G) Immunoblot of total protein from *DUX4*-expressing and control myoblasts (54-1 cells) treated with the proteasome inhibitor MG132 (10  $\mu$ M; 8 hr treatment initiated 16 hr after infection with lentiviral expression constructs). Loading control H3, histone 3, has a long half-life (Toyama et al., 2013). (H) Quantification of UPF1 protein levels from three independent replicates of the immunoblot presented in (G), normalized to the nonspecific band that serves as a loading control. Error bars, standard deviation.

DOI: [10.7554/eLife.04996.005](https://doi.org/10.7554/eLife.04996.005)


transcripts from the construct lacking the second intron of the *DUX4* 3' UTR increased only 1.5-fold. We conclude that the second intron of the *DUX4* 3' UTR is important for NMD-induced degradation of the *DUX4* mRNA (Figure 3F).

*DUX4* exhibits variegated expression in FSHD muscle cells, with only a few percent of nuclei detectable as *DUX4*+ (Snider et al., 2010). Therefore, augmented *DUX4* expression following *UPF1* KD in myotubes could be due to increases in *DUX4* mRNA in nuclei that are already *DUX4*+ and/or increases in the fraction of *DUX4*+ nuclei. Immunostaining of FSHD myotubes revealed that the fraction of *DUX4*+ nuclei increased from 0.3% to 2.1% following *UPF1* KD, a substantial order-of-magnitude increase (Figure 3G). Together, our data show that NMD is an endogenous suppressor of *DUX4* mRNA levels that contributes to the very low and variegated expression of *DUX4*, a characteristic feature of FSHD muscle cells.

As *DUX4* expression inhibits NMD and NMD degrades *DUX4* mRNA, we hypothesized that *DUX4* and the NMD pathway might participate in a double-negative feedback loop (Figure 4A). This feedback loop predicts that *DUX4* will indirectly stabilize its own mRNA by inhibiting NMD. To test this, we ectopically expressed *DUX4* in FSHD1 and FSHD2 myotubes and measured levels of endogenously transcribed *DUX4* mRNA. Ectopic *DUX4* expression led to an approximately fivefold increase in endogenously transcribed *DUX4* mRNA levels (Figure 4B). We next tested whether *DUX4*'s spliced 3' UTR, which is important for NMD-mediated degradation of *DUX4* mRNA, contributed to this increase. We transfected our chimeric  $\beta$ -globin + *DUX4* 3' UTR reporters into normal myoblasts and ectopically expressed *DUX4*. Levels of the NMD-susceptible construct containing the complete *DUX4* 3' UTR increased 1.43-fold following ectopic *DUX4* expression, while levels of the construct without the second intron of the *DUX4* 3' UTR exhibited a more modest increase of 1.08-fold (Figure 4C). As with the *UPF1* KD experiments, the chimeric construct exhibited more modest effect sizes in these feedback loop experiments than we observed for the endogenous *DUX4* mRNA itself.

Together, our data demonstrate that the *DUX4* 3' UTR targets *DUX4* mRNA for NMD and that *DUX4*-mediated inhibition of NMD results in increased perdurance of the *DUX4* mRNA as a possible mechanism of positive autoregulation (Figure 4D). It is unclear whether NMD-mediated autoregulation is intrinsic to normal *DUX4* function or instead an abnormal consequence of inappropriate *DUX4* expression in skeletal muscle. However, it is interesting to consider that this mechanism might contribute to the spreading of *DUX4* expression between adjacent nuclei in a muscle fiber. Because muscle fibers contain arrays of closely spaced nuclei, the expression of *DUX4* mRNA from one nucleus will distribute protein to the surrounding nuclei and induce a region of NMD inhibition. If one of the surrounding nuclei subsequently expresses *DUX4*, then that mRNA would be unusually stable due to locally inefficient NMD, thereby facilitating the spread of *DUX4* mRNA and protein throughout the fiber.

The close temporal coupling between the onset of *DUX4* expression, decreases in UPF1 protein, and increases in NMD substrates (Figure 2) strongly suggests that *DUX4*-mediated degradation of UPF1 contributes to *DUX4*-induced NMD inhibition. In the absence of a direct mechanistic link between UPF1 degradation and NMD inhibition, we were unable to determine whether insufficient UPF1 protein levels are primarily responsible for *DUX4*-induced NMD inhibition or instead merely one of the several contributing factors. Nonetheless, as we are unaware of other reports of physiological stimuli triggering rapid UPF1 protein degradation, our data suggest that UPF1 proteolysis constitutes a potential new regulator of cellular NMD efficiency. *DUX4* may prove a useful system to gain insight into the biological relevance of this mechanism for altering NMD efficiency. We previously observed




**Figure 3.** DUX4 mRNA is an endogenous NMD substrate. **(A)** Schematic of the DUX4 mRNA. Intron 2, constitutively spliced intron within the 3' UTR. Black, coding sequence; purple, 5' and 3' untranslated regions (UTRs). Red stop sign, termination codon. **(B)** Immunoblot of total protein from FSHD1 (54-2) and FSHD2 (MB200) myoblasts following transfection with a siRNA against *UPF1* or a control non-targeting siRNA.  $\alpha$ -tubulin, loading control. **(C)** Levels of DUX4 mRNA following control or *UPF1* knock-down, measured 2 days after the initiation of myogenesis. Error bars, standard deviation. **(D)** Levels of ZSCAN4 mRNA following control or *UPF1* knock-down, measured 2 days after the initiation of myogenesis. Error bars, standard deviation. **(E)** Schematic of chimeric constructs encoding the  $\beta$ -globin opening reading frame (cyan) followed by the DUX4 3' UTR (purple) containing (top) or lacking (bottom) the second intron of DUX4's 3' UTR (Intron 2). **(F)** Relative levels of transcripts from the GI-DUX4-Intron2(+) and GI-DUX4-Intron2(-) constructs following control or *UPF1* KD in normal myoblasts (54-1 cells). For each construct, data are normalized such that the siControl treatment is 1. Error bars, standard deviation. **(G)** Immunofluorescence with an antibody against DUX4 following control or *UPF1* knock-down, measured 2 days after the initiation of myogenesis in FSHD1 cells (54-2), which was prior to significant fusion. Box plot, percentage of DUX4+ nuclei as estimated by ImageJ (Fiji);  $n = 8$  fields. Whiskers, max and min over the fields.

DOI: 10.7554/eLife.04996.006

that many of the most up-regulated genes following DUX4 expression in normal myoblasts are involved in the ubiquitin–proteasome system, including numerous E3 ubiquitin ligases (Geng *et al.*, 2012). It is therefore tempting to speculate that DUX4-induced dysregulation of the ubiquitin–proteasome system is responsible for triggering *UPF1* protein degradation. However, the precise mechanism by which DUX4 induces *UPF1* proteolysis, and whether that mechanism is specific to the FSHD disease state, remains to be elucidated.

DUX4-mediated inhibition of NMD may contribute to FSHD pathophysiology through both cell autonomous and non-cell autonomous mechanisms. The accumulation of abnormal RNAs may cause direct or indirect toxic effects in muscle cells due to intrinsic toxicity of abnormal RNAs or a stress response to the production of abnormal proteins. FSHD muscle is frequently characterized by a T-cell infiltrate (Arahata *et al.*, 1995), and it is possible that stabilized NMD substrates encode novel peptides with antigenic potential, contributing to an immune response (Pastor *et al.*, 2010). Production of



**Figure 4.** *DUX4* and NMD form a feedback loop. **(A)** Schematic of potential double-negative feedback loop between *DUX4* and NMD, in which *DUX4* inhibits NMD and NMD degrades *DUX4* mRNA. **(B)** Levels of endogenously transcribed *DUX4* mRNA following control treatment or ectopic *DUX4* expression, measured 2 days after the initiation of myogenesis in FSHD1 (54-2) and FSHD2 (MB200) cells. **(C)** Relative levels of transcripts from the GI-*DUX4*-Intron2(+) and GI-*DUX4*-Intron2(-) constructs following control treatment or ectopic *DUX4* expression in normal myoblasts (54-1 cells). For each construct, data are normalized such that the siControl treatment is 1. Error bars, standard deviation. **(D)** Schematic of potential model of interactions between *DUX4* and NMD in healthy (top) and FSHD (bottom) muscle cells. In healthy cells, *DUX4* mRNA is efficiently degraded by NMD; in FSHD cells, *DUX4* triggers proteolytic degradation of UPF1 and inhibits NMD, resulting in the accumulation of *DUX4* mRNA and protein.

DOI: 10.7554/eLife.04996.007

antigenic peptides could potentially enable even a small fraction of *DUX4*+ nuclei to induce widespread pathology within a muscle fiber. Directly detecting or measuring *DUX4*-induced NMD inhibition in FSHD muscle biopsies or in bulk populations of cultured FSHD muscle cells is not feasible due to the low fraction of *DUX4*+ nuclei present at any given time in the absence of ectopic *DUX4* expression. With *DUX4*+ nuclei constituting only 0.3% of the bulk population of cultured FSHD muscle cells (**Figure 3G**), changes in the ratios of NMD and non-NMD isoforms in these *DUX4*+ nuclei are swamped by the normal levels expressed by the vast majority of *DUX4*- nuclei. Single-cell assays of NMD efficiency are likely required to demonstrate *DUX4*-induced NMD inhibition in unperturbed patient cells. However, future efforts to identify the downstream antigenic products or toxic effects of stabilized NMD substrates may prove fruitful even in a bulk cell population.

Consistent with the idea that NMD inhibition may contribute to *DUX4* toxicity in skeletal muscle, it is interesting to note that the degree of NMD inhibition induced by *DUX4* is comparable to that observed in previous studies involving genetic ablation of components of the NMD machinery. For example, a recent study of mouse embryonic fibroblasts lacking *Smg1*, which encodes a kinase responsible for phosphorylating UPF1, found that 9% of predicted NMD substrates created by alternative splicing exhibited increased levels relative to wild-type cells (**McIlwain et al., 2010**). In comparison, we found that 13% of such substrates were up-regulated following *DUX4* expression (**Figure 1**), suggesting that *DUX4*-induced NMD inhibition causes profoundly abnormal RNA metabolism. As RNA toxicity is the major pathophysiologic mechanism in myotonic dystrophy, it is interesting to consider that RNA-mediated disease mechanisms may also have important roles in FSHD.



## Materials and methods

### Accession codes

FASTQ files for the *DUX4* expression experiments were downloaded from the NCBI GEO database under accession number GSE45883 (Young *et al.*, 2013).

### Genome annotations

The UCSC knownGene (Meyer *et al.*, 2013) and Ensembl 71 (Flicek *et al.*, 2013) genome annotations were merged to create a single genome annotation. Splicing event annotations from MISO v2.0 (Katz *et al.*, 2010) were then added to this merged genome annotation. Constitutive splice junctions were defined as those for which neither the 5' nor 3' splice site was alternatively spliced in the UCSC knownGene annotation. Predicted NMD substrates were annotated by identifying isoforms containing premature termination codons >50 nt upstream of a splice junction. For the purposes of predicting NMD substrates, open reading frames were assigned based on UniProt annotations (UniProt Consortium, 2012) when available, and Ensembl predicted reading frames when UniProt annotations were not available. For the purposes of RNA-seq read mapping, an additional annotation file consisting of all splice junctions annotated in the UCSC, Ensembl 71, and MISO v2.0 annotations was created. This splice junction file was then with a list of all possible junctions between the annotated 5' and 3' splice sites of isoforms in the annotation (to detect novel alternative splicing).

### RNA-seq read mapping

Reads were mapped to the UCSC hg19 (NCBI GRCh37) genome assembly. RSEM (Li and Dewey, 2011) was modified to call Bowtie (Langmead *et al.*, 2009) v1.0.0 with the -v 2 argument. RSEM was then called with the arguments --bowtie-m 100 --bowtie-chunkmbs 500 --calc-ci --output-genome-bam on the genome annotation. Read alignments with mapq scores of 0 and/or a splice junction overhang of less than 6 bp were then filtered out. Remaining unaligned reads were then aligned TopHat (Trapnell *et al.*, 2009) v2.0.8b with the arguments --bowtie1 --read-mismatches 2 --read-edit-dist 2 --no-mixed --no-discordant --min-anchor-length 6 --splice-mismatches 0 --min-intron-length 10 --max-intron-length 1000000 --min-isoform-fraction 0.0 --no-novel-juncs --no-novel-indels --raw-juncs on the splice junction file (--mate-inner-dist and --mate-std-dev were calculated by mapping to constitutive coding exons with MISO's exon\_utils.py utility). Alignments produced by this call to TopHat were then filtered identically to the alignments produced by RSEM. Reads aligned by RSEM and TopHat were then merged to create BAM files of all aligned reads.

### Gene expression and isoform ratio measurements

Gene expression was quantified using RSEM as described above. Isoform ratios were quantified using two distinct methods. First, MISO was used to quantify isoform ratios for alternative splicing events contained in MISO's v2.0 annotations. Second, novel alternative splicing or intron retention of annotated constitutive splice junctions was quantified using reads crossing the 5' or 3' splice sites as previously described (Hubert *et al.*, 2013). Differentially spliced events were defined as those with at >20 identifying reads (identifying reads support one or more, but not all, isoforms of a splicing event), a change in isoform ratio  $\geq 10\%$ , and a Bayes factor  $\geq 5$  (computed with Wagenmakers's framework [Wagenmakers *et al.*, 2010]).

### Viral infection and cell culture

We used previously described lentiviral constructs expressing full-length *DUX4* or GFP as a control (Geng *et al.*, 2012). Lentiviral particles were generated by the FHCRC Core Center of Excellence in Hematology Vector Production Core. Viral particle number was estimated with the WPRE element within the viral vector. Myoblasts were transduced at a MOI of ~15 in the presence of 8  $\mu\text{g}/\text{ml}$  polybrene. At this MOI, >85% of myoblasts were *DUX4+* or *GFP+*. Unless otherwise noted, cells were collected for analysis 24 hr post-infection. Proliferating myoblasts were cultured in F-10-based growth media (Gibco, Carlsbad, CA) with 20% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco), supplemented with 10 ng/ml rhFGF (Promega, Madison, WI) and 1  $\mu\text{M}$  dexamethasone (Sigma, St. Louis, MO). Growth media was changed every other day, and proliferating myoblasts were cultured at  $\leq 50\%$  confluence. To initiate myogenic differentiation, myoblasts were switched to an F-10-based differentiation media containing 1% horse serum (Gibco) and 1% penicillin/streptomycin, supplemented with 10  $\mu\text{g}/\text{ml}$  insulin (Sigma) and 10  $\mu\text{g}/\text{ml}$  transferrin (Sigma) at 99% confluence.

## Plasmid and siRNA transfection

The  $\beta$ -globin NMD(-) and NMD(+) plasmids were previously published as pmCMV-GI Norm and pmCMV-GI 39Ter (Zhang *et al.*, 1998). Plasmid reporters were transfected with Lipofectamine 2000 (Life Technologies, Carlsbad, CA), unless otherwise noted. To control for transfection efficiency, a control plasmid phCMV-MUP was co-transfected with the reporter as previously described (Zhang *et al.*, 1998). 2  $\mu$ g of reporter along with 500 ng of control plasmid was used for transfecting cells in a six-well format. To measure DUX4-induced changes in NMD efficiency, cells were infected with lentiviral DUX4 or GFP 24 hr after transfection of the NMD reporters. For the DUX4 time course experiments, the NMD(-) and NMD(+) reporters were transfected along with phCMV-MUP using the SuperFect reagent (Qiagen, Valencia, CA), and the lentiviral transduction was performed 12 hr post-transfection. siRNAs against UPF1 (Thermo Scientific, Waltham, MA, On-Target siRNA #J-011763-07) and TP53 (Ambion, Silencer Select siRNA #4390824), as well as the control siRNA (Thermo Scientific), were transfected with Lipofectamine RNAiMAX (Life Technologies).

## RNA isolation, real-time qPCR, and endogenous DUX4 mRNA measurement

Cells were lysed with TRIzol (Invitrogen, Carlsbad, CA) and the RNA was extracted according to the manufacturer's instructions. RNA was subsequently cleaned up with Qiagen RNeasy columns, with on-column DNase digestion. 1  $\mu$ g of RNA was used for cDNA synthesis with Life Technologies SuperScriptIII First-Strand System. 2% of this cDNA was used as a template for real-time qPCR with Life Technologies Power SYBR Green Master Mix. qPCR primer sequences are provided in **Supplementary file 1**. Note that levels of endogenous DUX4 mRNA following ectopic DUX4 expression were measured with primers specific to the DUX4 mRNA's 3' UTR (the DUX4 lentiviral construct contained the coding sequence alone). To determine how UPF1 KD affected DUX4 expression, proliferating 54-2 or MB200 myoblasts were transfected with siUPF1 or siControl and switched to differentiation media 48 hr post-transfection.

## Western blotting

Protein extracts from the UPF1 KD experiments were generated by lysing cell pellets in protease inhibitor cOmplete ULTRA (Roche, Switzerland) containing RIPA buffer (Cell Signaling Technology, Danvers, MA) along with sonication. For the DUX4 time course and MG132 treatment, protein was extracted in parallel with the RNA from cells lysed in the TRIzol reagent. Protein pellets were resuspended in a sample buffer containing 5% SDS and 0.5 M unbuffered Tris base to ensure efficient solubilization. Protein concentrations were determined using the Bradford or BCA protein assay. 5  $\mu$ g of total protein was used for Western blotting. Antibodies used in this study are: anti-UPF1 (Bethyl Laboratories, Montgomery, TX), anti- $\alpha$ -tubulin (Sigma), anti-H3 (Abcam, England), anti-UPF3B (Bethyl Laboratories), anti-SMG7 (Santa Cruz, Dallas, TX). HRP-conjugated (Jackson ImmunoResearch, West Grove, PA) secondary antibodies were used for protein detection in all experiments except for the time course and proteasome inhibitor studies (Figure 2). For the experiments reported in Figure 2, immunoblotting was performed using the LICOR system with the Odyssey blocking buffer and IRDye-conjugated secondary antibodies (LICOR, Lincoln, NE). Quantification was performed using ImageQuant software (GE Healthcare, Cleveland, OH) using the nonspecific band as a normalizer to account for differences in protein loading. Histone 3 served as an additional loading control, though its very high signal intensity made it an inappropriate normalizer for quantitative analyses.

## Proteasome inhibition

54-1 cells transduced with DUX4 or GFP lentivirus were treated 16 hr post-infection with 10  $\mu$ M proteasome inhibitor MG132 (Sigma). Samples were collected 8 hr after MG132 treatment, and UPF1 levels were estimated by immunoblotting. Histone H3, which has a long half-life (Toyama *et al.*, 2013), was used as a loading control, in addition to the nonspecific band.

## Fluorescence microscopy and quantification

Cells were permeabilized with PBS containing 0.5% Triton X-100, rinsed in PBS, and blocked in 1% BSA. Primary antibody against DUX4 (Abcam, ab124699) was diluted in blocking buffer at 1:500, and secondary anti-Rabbit TRITC (Jackson ImmunoResearch, 711-025-152) was diluted in blocking buffer at 1:400. For assaying apoptosis in DUX4-cells, Image-iT LIVE Red Poly Caspases Detection Kit (Life Technologies, I35101) was used. For both experiments, fluorescently labeled cells were then

viewed under the ZEISS Axiophot fluorescence microscope. For each sample, pictures from eight random fields were taken. ImageJ (Fiji) was used for image analysis and quantification.

## Cloning of chimeric $\beta$ -globin + DUX4 3' UTR constructs

The genomic locus of the *DUX4* 3' UTR (containing both introns) was amplified from a genomic fragment harboring 2.5 D4Z4 repeats (*Gabriëls et al., 1999*) (L42 clone; GenBank ID FJ439133.1). The *DUX4* 3' UTR lacking the second intron was amplified from cDNA isolated from differentiated 54-2 cells (the first intron is frequently retained in *DUX4* cDNA). The  $\beta$ -globin NMD(-) reporter backbone was linearized by forward and reverse PCR primers sitting downstream and upstream of the  $\beta$ -globin 3' UTR (primers listed in **Supplementary file 1**). Amplicons of the *DUX4* 3' UTR containing or lacking the second intron were flanked with sequences overlapping the linearized  $\beta$ -globin NMD(-) backbone lacking the  $\beta$ -globin 3' UTR. The NEB Gibson Assembly Cloning Kit was used to insert the *DUX4* 3' UTR fragments into the linearized  $\beta$ -globin NMD(-) backbone (New England Biolabs, Ipswich, MA).

## Acknowledgements

We thank Lynne Maquat for sharing the  $\beta$ -globin NMD reporter and MUP transfection control plasmids. This research was supported by the Damon Runyon Cancer Research Foundation DFS 04-12 (RKB), the Ellison Medical Foundation AG-NS-1030-13 (RKB), Fred Hutchinson Cancer Research Center institutional funds (RKB), Friends of FSH Research (SJT), NIH/NIAMS R01AR045203 (SJT), and NIH/NINDS P01NS069539 (SJT).

---

## Additional information

### Funding

Funder	Grant reference number	Author
Damon Runyon Cancer Research Foundation	DFS 04-12	Robert K Bradley
Ellison Medical Foundation	AG-NS-1030-13	Robert K Bradley
Friends of FSH Research		Stephen J Tapscott
National Institutes of Health	R01AR045203	Stephen J Tapscott
National Institutes of Health	P01NS069539	Stephen J Tapscott

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

### Author contributions

QF, Performed NMD inhibition experiments and computational analyses, and created **Figures 1, 3, and 4**; LS, Performed NMD inhibition experiments; SJ, Identified UPF1 proteolysis and created **Figure 2**; RT, SMM, Provided critical biological reagents and information; SJT, Provided overall oversight of the project; RKB, Performed computational analyses and provided overall oversight of the project

### Author ORCIDs

Robert K Bradley,  <http://orcid.org/0000-0002-8046-1063>

---

## Additional files

### Supplementary file

- Supplementary file 1. Primer sequences used for cloning and real-time PCR assays. List of primers used for cloning and real-time PCR. GENE ID, Ensembl ID for the tested genes. RPL27 and SRP14: housekeeping genes. HNRNPD, SRSF2, and SRSF3: inclusion primer sets measure levels of endogenously produced NMD-degraded isoforms. Endogenous *DUX4* mRNA was measured with primers specific to its 3' UTR (RKB\_929 and RKB\_930). Expression from chimeric GI-DUX4-Intron2(+) and GI-DUX4-Intron2(-) constructs was measured with primers specific to the spliced  $\beta$ -globin region.

DOI: [10.7554/eLife.04996.008](https://doi.org/10.7554/eLife.04996.008)

## Major dataset

The following previously published dataset was used:

Author(s)	Year	Dataset title	Dataset ID and/or URL	Database, license, and accessibility information
Young JM, Whiddon JL, Yao Z, Kasinathan B, Snider L, Geng LN, Tawil R, van der Maarel SM, Tapscott SJ	2013	Retroelements and DUX4 Create Primate-specific Promoters for Germline Genes	<a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45883">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45883</a>	Publicly available at NCBI Gene Expression Omnibus.

## References

- Arahata K**, Ishihara T, Fukunaga H, Orimo S, Lee JH, Goto K, Nonaka I. 1995. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. *Muscle & Nerve. Supplement* 2:S56–S66. doi: [10.1002/mus.880181312](https://doi.org/10.1002/mus.880181312).
- Cowan JL**, Morley SJ. 2004. The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complex. *European Journal of Biochemistry* 271:3596–3611. doi: [10.1111/j.0014-2956.2004.04306.x](https://doi.org/10.1111/j.0014-2956.2004.04306.x).
- Flicek P**, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, Gil L, García-Girón C, Gordon L, Hourlier T, Hunt S, Juettemann T, Kähäri AK, Keenan S, Komorowska M, Kulesha E, Longden I, Maurel T, McLaren WM, Muffato M, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ritchie GR, Ruffier M, Schuster M, Sheppard D, Sobral D, Taylor K, Thormann A, Trevanion S, White S, Wilder SP, Aken BL, Birney E, Cunningham F, Dunham I, Harrow J, Herrero J, Hubbard TJ, Johnson N, Kinsella R, Parker A, Spudich G, Yates A, Zadissa A, Searle SM. 2013. Ensembl 2013. *Nucleic Acids Research* 41:D48–D55. doi: [10.1093/nar/gks1236](https://doi.org/10.1093/nar/gks1236).
- Gabriëls J**, Beckers MC, Ding H, De Vriese A, Plaisance S, van der Maarel SM, Padberg GW, Frants RR, Hewitt JE, Collen D, Belayew A. 1999. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 236:25–32. doi: [10.1016/S0378-1119\(99\)00267-X](https://doi.org/10.1016/S0378-1119(99)00267-X).
- Geng LN**, Yao Z, Snider L, Fong AP, Cech JN, Young JM, van der Maarel SM, Ruzzo WL, Gentleman RC, Tawil R, Tapscott SJ. 2012. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. *Developmental Cell* 22:38–51. doi: [10.1016/j.devcel.2011.11.013](https://doi.org/10.1016/j.devcel.2011.11.013).
- Huang L**, Lou CH, Chan W, Shum EY, Shao A, Stone E, Karam R, Song HW, Wilkinson MF. 2011. RNA Homeostasis Governed by cell type-specific and Branched feedback loops acting on NMD. *Molecular Cell* 43:950–961. doi: [10.1016/j.molcel.2011.06.031](https://doi.org/10.1016/j.molcel.2011.06.031).
- Hubert CG**, Bradley RK, Ding Y, Toledo CM, Herman J, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P, Hardcastle J, Basom R, Delrow JJ, Webb T, Pollard SM, Lee J, Olson JM, Paddison PJ. 2013. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. *Genes & Development* 27:1032–1045. doi: [10.1101/gad.212548.112](https://doi.org/10.1101/gad.212548.112).
- Katz Y**, Wang ET, Airoidi EM, Burge CB. 2010. Analysis and design of RNA sequencing experiments for identifying isoform regulation. *Nature Methods* 7:1009–1015. doi: [10.1038/nmeth.1528](https://doi.org/10.1038/nmeth.1528).
- Kowaljaw V**, Marcowycz A, Anseau E, Conde CB, Sauvage S, Mattéotti C, Arias C, Corona ED, Nuñez NG, Leo O, Wattiez R, Figlewicz D, Laoudj-Chenivresse D, Belayew A, Coppée F, Rosa AL. 2007. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. *Neuromuscular Disorders* 17:611–623. doi: [10.1016/j.nmd.2007.04.002](https://doi.org/10.1016/j.nmd.2007.04.002).
- Krom YD**, Dumonceaux J, Mamchaoui K, Hamer den B, Mariot V, Negroni E, Geng LN, Martin N, Tawil R, Tapscott SJ, van Engelen BG, Mouly V, Butler-Browne GS, van der Maarel SM. 2012. Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. *The American Journal of Pathology* 181:1387–1401. doi: [10.1016/j.ajpath.2012.07.007](https://doi.org/10.1016/j.ajpath.2012.07.007).
- Langmead B**, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biology* 10:R25. doi: [10.1186/gb-2009-10-3-r25](https://doi.org/10.1186/gb-2009-10-3-r25).
- Lareau LF**, Inada M, Green RE, Wengrod JC, Brenner SE. 2007. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. *Nature* 446:926–929. doi: [10.1038/nature05676](https://doi.org/10.1038/nature05676).
- Lemmers RJ**, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, Amell AM, van der Vliet PJ, Almomani R, Straasheijm KR, Krom YD, Klooster R, Sun Y, den Dunnen JT, Helmer Q, Donlin-Smith CM, Padberg GW, van Engelen BG, de Greef JC, Aartsma-Rus AM, Frants RR, de Visser M, Desnuelle C, Sacconi S, Filippova GN, Bakker B, Bamshad MJ, Tapscott SJ, Miller DG, van der Maarel SM. 2012. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. *Nature Genetics* 44:1370–1374. doi: [10.1038/ng.2454](https://doi.org/10.1038/ng.2454).
- Lemmers RJ**, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, Tawil R, Frants RR, van der Maarel SM. 2010. A unifying genetic model for facioscapulohumeral muscular dystrophy. *Science* 329:1650–1653. doi: [10.1126/science.1189044](https://doi.org/10.1126/science.1189044).
- Li B**, Dewey CN. 2011. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 12:323. doi: [10.1186/1471-2105-12-323](https://doi.org/10.1186/1471-2105-12-323).

- Mazroui R**, Di Marco S, Kaufman RJ, Gallouzi IE. 2007. Inhibition of the ubiquitin-proteasome system induces stress granule formation. *Molecular Biology of the Cell* **18**:2603–2618. doi: [10.1091/mbc.E06-12-1079](https://doi.org/10.1091/mbc.E06-12-1079).
- McIlwain DR**, Pan Q, Reilly PT, Elia AJ, McCracken S, Wakeham AC, Itie-Youten A, Blencowe BJ, Mak TW. 2010. Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay. *Proceedings of the National Academy of Sciences of USA* **107**:12186–12191. doi: [10.1073/pnas.1007336107](https://doi.org/10.1073/pnas.1007336107).
- Meyer LR**, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, Raney BJ, Pohl A, Malladi VS, Li CH, Lee BT, Learned K, Kirkup V, Hsu F, Heitner S, Harte RA, Haeussler M, Guruvadoo L, Goldman M, Giardine BM, Fujita PA, Dreszer TR, Diekhans M, Cline MS, Clawson H, Barber GP, Haussler D, Kent WJ. 2013. The UCSC Genome Browser database: extensions and updates 2013. *Nucleic Acids Research* **41**:D64–D69. doi: [10.1093/nar/gks1048](https://doi.org/10.1093/nar/gks1048).
- Mitsuhashi H**, Mitsuhashi S, Lynn-Jones T, Kawahara G, Kunkel LM. 2012. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. *Human Molecular Genetics* **22**:568–577. doi: [10.1093/hmg/dds467](https://doi.org/10.1093/hmg/dds467).
- Ni JZ**, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, Shiue L, Clark TA, Blume JE, Ares M. 2007. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. *Genes & Development* **21**:708–718. doi: [10.1101/gad.1525507](https://doi.org/10.1101/gad.1525507).
- Pastor F**, Kolonias D, Giangrande PH, Gilboa E. 2010. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. *Nature* **465**:227–230. doi: [10.1038/nature08999](https://doi.org/10.1038/nature08999).
- Schoenberg DR**, Maquat LE. 2012. Regulation of cytoplasmic mRNA decay. *Nature Reviews. Genetics* **13**:246–259. doi: [10.1038/nrg3254](https://doi.org/10.1038/nrg3254).
- Snider L**, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG. 2010. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. *PLOS Genetics* **6**:e1001181. doi: [10.1371/journal.pgen.1001181](https://doi.org/10.1371/journal.pgen.1001181).
- Toyama BH**, Savas JN, Park SK, Harris MS, Ingolia NT, Yates JR, Hetzer MW. 2013. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. *Cell* **154**:971–982. doi: [10.1016/j.cell.2013.07.037](https://doi.org/10.1016/j.cell.2013.07.037).
- Trapnell C**, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**:1105–1111. doi: [10.1093/bioinformatics/btp120](https://doi.org/10.1093/bioinformatics/btp120).
- UniProt Consortium**. 2012. Reorganizing the protein space at the Universal Protein Resource (UniProt). *Nucleic Acids Research* **40**:D71–D75. doi: [10.1093/nar/gkr981](https://doi.org/10.1093/nar/gkr981).
- Vanderplanck C**, Anseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivresse D, Wilton SD, Coppée F, Belayew A. 2011. The FSHD atrophic myotube phenotype is caused by DUX4 expression. *PLOS ONE* **6**:e26820. doi: [10.1371/journal.pone.0026820](https://doi.org/10.1371/journal.pone.0026820).
- Wagenmakers EJ**, Lodewyckx T, Kuriyal H, Grasman R. 2010. Bayesian hypothesis testing for psychologists: a tutorial on the Savage-Dickey method. *Cognitive Psychology* **60**:158–189. doi: [10.1016/j.cogpsych.2009.12.001](https://doi.org/10.1016/j.cogpsych.2009.12.001).
- Wallace LM**, Garwick SE, Mei W, Belayew A, Coppée F, Ladner KJ, Guttridge D, Yang J, Harper SQ. 2011. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. *Annals of Neurology* **69**:540–552. doi: [10.1002/ana.22275](https://doi.org/10.1002/ana.22275).
- Weischenfeldt J**, Waage JE, Tian G, Zhao J, Damgaard I, Jakobsen JS, Kristiansen K, Krogh A, Wang J, Porse BT. 2012. Mammalian tissues defective in nonsense-mediated mRNA decay display highly aberrant splicing patterns. *Genome Biology* **13**:R35. doi: [10.1186/gb-2012-13-5-r35](https://doi.org/10.1186/gb-2012-13-5-r35).
- Young JM**, Whiddon JL, Yao Z, Kasinathan B, Snider L, Geng LN, Balog J, Tawil R, van der Maarel SM, Tapscott SJ. 2013. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. *PLOS Genetics* **9**:e1003947. doi: [10.1371/journal.pgen.1003947](https://doi.org/10.1371/journal.pgen.1003947).
- Zhang J**, Sun X, Qian Y, Maquat LE. 1998. Intron function in the nonsense-mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence mRNA translation in the cytoplasm. *RNA* **4**:801–815. doi: [10.1017/S1355838298971849](https://doi.org/10.1017/S1355838298971849).